First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.

First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. Clin Cancer Res. 2017 07 01; 23(13):3269-3276.

View in: PubMed

subject areas

Administration, Oral
Adult
Aged
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug-Related Side Effects and Adverse Reactions
Female
Humans
Indoleamine-Pyrrole 2,3,-Dioxygenase
Male
Middle Aged
Neoplasm Staging
Neoplasms
Oximes
Sulfonamides

authors with profiles

Thomas F. Gajewski